Ultragenyx Pharmaceutical Inc., established on April 22, 2010, is a developing-stage biotechnology company, which was subsequently re-incorporated in Delaware in June 2011. The company focuses on the identification, acquisition, development and commercialization of novel products for the treatment of rare and very rare diseases, with the original goal of the products for the treatment of severe, debilitating metabolic genetic diseases. The company's sustained-release sialic acid is currently in the second phase of clinical trials for the treatment of patients with hereditary inclusion body myopathy, a progressive muscle-wasting disease. 

RARE

RARE Profile